Literature DB >> 15100281

Cathepsin-dependent apoptosis triggered by supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance.

Marie-Cécile Michallet1, Frédéric Saltel, Monique Flacher, Jean-Pierre Revillard, Laurent Genestier.   

Abstract

High doses of Ag can paradoxically suppress immune responses in vivo. This Ag-specific unresponsiveness (termed high dose tolerance) involves extrathymic mechanisms in mature T lymphocytes. To investigate these mechanisms, we used the in vitro model of PBL activated with anti-CD3 or PHA. In these conditions, increasing mitogen concentrations resulted in a reduction of the proliferative response, associated with an increased percentage of apoptotic cells. Apoptosis did not require prior exposure to IL-2, it was not the consequence of CD178/CD95 or TNF/TNFR interactions, and was therefore clearly distinct from activation-induced cell death. Although the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) decreased DNA fragmentation, cytochrome c release and caspase-9 and caspase-3 activation were not implicated, suggesting that this apoptosis did not primarily involve the intrinsic mitochondrial pathway. E64d, a cysteine protease inhibitor, as well as specific inhibitors of cathepsin B and cathepsin L conferred protection. We further demonstrated that cathepsin B and cathepsin L were released from the lysosomes and catalytically active in the cytosol. Release of cathepsin B and cathepsin L was the consequence of lysosomal membrane permeabilization without complete disruption of the cytosol-lysosome pH gradient. These results demonstrate a role for cathepsins in supraoptimal activation-induced apoptosis in vitro and suggest their possible participation in high dose tolerance in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100281     DOI: 10.4049/jimmunol.172.9.5405

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway.

Authors:  Fabio Rabelo Melo; Ida Waern; Elin Rönnberg; Magnus Åbrink; David M Lee; Susan M Schlenner; Thorsten B Feyerabend; Hans-Reimer Rodewald; Boris Turk; Sara Wernersson; Gunnar Pejler
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 2.  Endolysosomal proteases and their inhibitors in immunity.

Authors:  Phillip I Bird; Joseph A Trapani; José A Villadangos
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

3.  Imbalance between cysteine proteases and inhibitors in a baboon model of bronchopulmonary dysplasia.

Authors:  Ozden Altiok; Ryuji Yasumatsu; Gulbin Bingol-Karakoc; Richard J Riese; Mildred T Stahlman; William Dwyer; Richard A Pierce; Dieter Bromme; Ekkehard Weber; Sule Cataltepe
Journal:  Am J Respir Crit Care Med       Date:  2005-09-15       Impact factor: 21.405

4.  Lysosomal destabilization contributes to apoptosis of germinal center B-lymphocytes.

Authors:  Kirsten van Nierop; Femke J M Muller; Jan Stap; Cornelis J F Van Noorden; Marco van Eijk; Cornelis de Groot
Journal:  J Histochem Cytochem       Date:  2006-09-06       Impact factor: 2.479

5.  Death receptor ligation triggers membrane scrambling between Golgi and mitochondria.

Authors:  S Ouasti; P Matarrese; R Paddon; R Khosravi-Far; M Sorice; A Tinari; W Malorni; M Degli Esposti
Journal:  Cell Death Differ       Date:  2006-09-29       Impact factor: 15.828

6.  Serglycin proteoglycan promotes apoptotic versus necrotic cell death in mast cells.

Authors:  Fabio R Melo; Mirjana Grujic; Jane Spirkoski; Gabriela Calounova; Gunnar Pejler
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

7.  Early divergence in neutrophil apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates.

Authors:  Carole Elbim; Valerie Monceaux; Yvonne M Mueller; Mark G Lewis; Stephanie François; Ousmane Diop; Khadija Akarid; Bruno Hurtrel; Marie-Anne Gougerot-Pocidalo; Yves Lévy; Peter D Katsikis; Jerome Estaquier
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 8.  Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

Authors:  Emilie M J van Brummelen; Willeke Ros; Gertjan Wolbink; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2016-07-20

9.  Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.

Authors:  Said A Jongo; L W Preston Church; Ali T Mtoro; Tobias Schindler; Sumana Chakravarty; Adam J Ruben; Phillip A Swanson; Kamaka R Kassim; Maximillian Mpina; Anneth-Mwasi Tumbo; Florence A Milando; Munira Qassim; Omar A Juma; Bakari M Bakari; Beatus Simon; Eric R James; Yonas Abebe; Natasha Kc; Elizabeth Saverino; Martina Fink; Glenda Cosi; Linda Gondwe; Fabian Studer; David Styers; Robert A Seder; Tobias Schindler; Peter F Billingsley; Claudia Daubenberger; B Kim Lee Sim; Marcel Tanner; Thomas L Richie; Salim Abdulla; Stephen L Hoffman
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

10.  Cathepsin B controls the persistence of memory CD8+ T lymphocytes.

Authors:  Susan M Byrne; Anne Aucher; Syarifah Alyahya; Matthew Elder; Steven T Olson; Daniel M Davis; Philip G Ashton-Rickardt
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.